Optimal data-driven policies for disease screening under noisy biomarker measurement

References

• Aissi, H., Bazgan, C. and Vanderpooten, D. (2006) Approximating min-max (regret) versions of some polynomial problems, in International Computing and Combinatorics Conference, Springer, Berlin, Heidelberg, pp. 428–438.
   Google Scholar
• Atrash, S., Robinson, M.M., Aneralla, A., Brown, T., Friend, R., Sprouse, C., Ndiaye, A., Zhang, Q., Lipford, E.H., Block, J.G. and Smith, E.T. (2017) Validation of dynamic biomarker-based risk progression model for smoldering multiple myeloma. Blood, 130, 1779.
   Web of Science ®Google Scholar
• Austin, P.C., Tu, J.V., Ho, J.E., Levy, D. and Lee, D.S. (2013) Using methods from the data-mining and machine-learning literature for disease classification and prediction: A case study examining classification of heart failure subtypes. Journal of Clinical Epidemiology, 66(4), 398–407.
   PubMed Web of Science ®Google Scholar
• Averbakh, I. (2004) Minmax regret linear resource allocation problems. Operations Research Letters, 32(2), 174–180.
   Web of Science ®Google Scholar
• Ayer, T., Alagoz, O. and Stout, N.K. (2012) OR Forum—A POMDP approach to personalize mammography screening decisions. Operations Research, 60(5), 1019–1034.
   Web of Science ®Google Scholar
• Ayer, T., Alagoz, O., Stout, N.K. and Burnside, E.S. (2015) Heterogeneity in women’s adherence and its role in optimal breast cancer screening policies. Management Science, 62(5), 1339–1362.
   Web of Science ®Google Scholar
• Ayvaci, M.U., Alagoz, O. and Burnside, E.S. (2012) The effect of budgetary restrictions on breast cancer diagnostic decisions. Manufacturing & Service Operations Management, 14(4), 600–617.
   Google Scholar
• Ayvaci, M.U.S., Ahsen, M.E., Raghunathan, S. and Gharibi, Z. (2017) Timing the use of breast cancer risk information in biopsy decision-making. Production and Operations Management, 26(7), 1333–1358.
   Web of Science ®Google Scholar
• Bacus, S. and Spector, N. (2007) Biomarkers in cancer. US Patent App. 10/568,251.
   Google Scholar
• Baker, M.W., Atkins, A.E., Cordovado, S.K., Hendrix, M., Earley, M.C. and Farrell, P.M. (2016) Improving newborn screening for cystic fibrosis using next-generation sequencing technology: A technical feasibility study. Genetics in Medicine, 18(3), 231–238.
   PubMed Web of Science ®Google Scholar
• Barnett, C.L., Tomlins, S.A., Underwood, D.J., Wei, J.T., Morgan, T.M., Montie, J.E. and Denton, B.T. (2017) Two-stage biomarker protocols for improving the precision of early detection of prostate cancer. Medical Decision Making, 37(7), 815–826.
   Web of Science ®Google Scholar
• Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Berezina, T.A. and Samura, T.A. (2015) The utility of biomarker risk prediction score in patients with chronic heart failure. Clinical Hypertension, 22(1), 3–13.
   Google Scholar
• Bertsimas, D., Brown, D.B. and Caramanis, C. (2011) Theory and applications of robust optimization. SIAM Review, 53(3), 464–501.
   Web of Science ®Google Scholar
• Bertsimas, D., Silberholz, J. and Trikalinos, T. (2018) Optimal healthcare decision making under multiple mathematical models: Application in prostate cancer screening. Healthcare Management Science, 21(1), 105–118.
   Web of Science ®Google Scholar
• Bonaccorso, G. (2017) Machine Learning Algorithms. Packt Publishing Ltd.
   Google Scholar
• Castellani, C., Massie, J., Sontag, M. and Southern, K.W. (2016) Newborn screening for cystic fibrosis. The Lancet Respiratory Medicine, 4(8), 653–661.
   PubMed Web of Science ®Google Scholar
• Comeau, A.M., Accurso, F.J., White, T.B., Campbell, P.W., Hoffman, G., Parad, R.B., Wilfond, B.S., Rosenfeld, M., Sontag, M.K., Massie, J. et al. (2007) Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics, 119(2), e495–e518.
   PubMed Web of Science ®Google Scholar
• Comeau, A.M., Parad, R.B., Dorkin, H.L., Dovey, M., Gerstle, R., Haver, K., Lapey, A., O’Sullivan, B.P., Waltz, D.A., Zwerdling, R.G., and Eaton, R.B. (2004) Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: A cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics, 113(6), 1573–1581.
   PubMed Web of Science ®Google Scholar
• Currier, R.J., Sciortino, S., Liu, R., Bishop, T., Koupaei, R.A. and Feuchtbaum, L. (2017) Genomic sequencing in cystic fibrosis newborn screening: What works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing? Genetics in Medicine, 19(10), 1159–1163.
   Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. https://www.cff.org/, accessed April 2018.
   Google Scholar
• Deneef, P. and Kent, D.L. (1993) Using treatment-tradeoff preferences to select diagnostic strategies: Linking the ROC curve to threshold analysis. Medical Decision Making, 13(2), 126–132.
   Web of Science ®Google Scholar
• Dijk, F.N., McKay, K., Barzi, F., Gaskin, K.J. and Fitzgerald, D.A. (2011) Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Archives of Disease in Childhood, 96(12), 1118–1123.
   Web of Science ®Google Scholar
• Dodd, R., Notari, E. and Stramer, S. (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42(8), 975–979.
   Web of Science ®Google Scholar
• Doecke, J.D., Laws, S.M., Faux, N.G., Wilson, W., Burnham, S.C., Lam, C.P., Mondal, A., Bedo, J., Bush, A.I., Brown, B. and De Ruyck, K. (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Archives of Neurology, 69(10), 1318–1325.
   PubMedGoogle Scholar
• Draper, N.R. and Smith, H. (1998) Selecting the “best” regression equation. Applied Regression Analysis, 327–368.
   Google Scholar
• El-Amine, H., Bish, E.K., and Bish, D.R. (2018) Robust postdonation blood screening under prevalence rate uncertainty. Operations Research, 66(1), 1–17.
   Web of Science ®Google Scholar
• Farrell, P.M., Kosorok, M.R., Rock, M.J., Laxova, A., Zeng, L., Lai, H., Hoffman, G., Laessig, R.H., Splaingard, M.L., Wisconsin Cystic Fibrosis Neonatal Screening Study Group and others (2001) Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics, 107(1), 1–13.
   PubMed Web of Science ®Google Scholar
• Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., Durie, P.R., LeGrys, V.A., Massie, J., Parad, R.B. and Rock, M.J. (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. The Journal of Pediatrics, 153(2), S4–S14.
   PubMed Web of Science ®Google Scholar
• Felder, S. and Mayrhofer, T. (2014) Risk preferences: Consequences for test and treatment thresholds and optimal cutoffs. Medical Decision Making, 34(1), 33–41.
   Web of Science ®Google Scholar
• Fluss, R., Faraggi, D. and Reiser, B. (2005) Estimation of the Youden Index and its associated cutoff point. Biometrical Journal, 47(4), 458–472.
   PubMed Web of Science ®Google Scholar
• Greiner, M., Sohr, D. and Göbel, P. (1995) A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. Journal of Immunological Methods, 185(1), 123–132.
   Web of Science ®Google Scholar
• Hammond, K.B., Abman, S.H., Sokol, R.J. and Accurso, F.J. (1991) Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. New England Journal of Medicine, 325(11), 769–774.
   PubMed Web of Science ®Google Scholar
• Higgins, T.L., Estafanous, F.G., Loop, F.D., Beck, G.J., Blum, J.M. and Paranandi, L. (1992) Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: A clinical severity score. JAMA, 267(17), 2344–2348.
   Web of Science ®Google Scholar
• Jiang, W., Freidlin, B. and Simon, R. (2007) Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute, 99(13), 1036–1043.
   Google Scholar
• Jund, J., Rabilloud, M., Wallon, M. and Ecochard, R. (2005) Methods to estimate the optimal threshold for normally or log-normally distributed biological tests. Medical Decision Making, 25(4), 406–415.
   Web of Science ®Google Scholar
• Kammesheidt, A., Kharrazi, M., Graham, S., Young, S., Pearl, M., Dunlop, C. and Keiles, S. (2006) Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens–implications for newborn screening. Genetics in Medicine, 8(9), 557–562.
   Web of Science ®Google Scholar
• Kharrazi, M., Yang, J., Bishop, T., Lessing, S., Young, S., Graham, S., Pearl, M., Chow, H., Ho, T., Currier, R. and Gaffney, L. (2015). Newborn screening for cystic fibrosis in California. Pediatrics, 136(6), 1062–1072.
   PubMed Web of Science ®Google Scholar
• Kloosterboer, M., Hoffman, G., Rock, M., Gershan, W., Laxova, A., Li, Z. and Farrell, P.M. (2009) Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics, 123(2), e338–e346.
   PubMed Web of Science ®Google Scholar
• Kucirka, L.M., Sarathy, H., Govindan, P., Wolf, J.H., Ellison, T.A., Hart, L.J., Montgomery, R.A., Ros, R.L. and Segev, D.L. (2011) Risk of window period HIV infection in high infectious risk donors: Systematic review and meta-analysis. American Journal of Transplantation, 11(6), 1176–1187.
   Web of Science ®Google Scholar
• Kuhn, M. and Johnson, K. (2013) Applied Predictive Modeling, Vol. 26, Springer, New York.
   Google Scholar
• Massie, J., Curnow, L., Tzanakos, N., Francis, I. and Robertson, C.F. (2006) Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Archives of Disease in Childhood, 91(3), 222–225.
   Web of Science ®Google Scholar
• Mastin, A., Jaillet, P. and Chin, S. (2015) Randomized minmax regret for combinatorial optimization under uncertainty, in International Symposium on Algorithms and Computation, Springer, Berlin, Heidelberg, pp. 491–501.
   Google Scholar
• Mayeux, R. (2004) Biomarkers: Potential uses and limitations. NeuroRx, 1(2), 182–188.
   PubMedGoogle Scholar
• McMahan, C.S., Tebbs, J.M. and Bilder, C.R. (2012). Regression models for group testing data with pool dilution effects. Biostatistics, 14(2), 284–298.
   Web of Science ®Google Scholar
• Paracchini, V., Seia, M., Raimondi, S., Costantino, L., Capasso, P., Porcaro, L., Colombo, C., Coviello, D.A., Mariani, T., Manzoni, E. and Sangiovanni, M. (2011) Cystic fibrosis newborn screening: Distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates, in JIMD Reports-Case and Research Reports, 2012/1, Springer, Berlin, Heidelberg, pp.17–23.
   Google Scholar
• Pauker, S.G. and Kassirer, J.P. (1980) The threshold approach to clinical decision making. New England Journal of Medicine, 302(20), 1109–1117.
   PubMed Web of Science ®Google Scholar
• Pepe, M.S. (2003) The Statistical Evaluation of Medical Tests for Classification and Prediction, Medicine.
   Google Scholar
• Perakis, G. and Roels, G. (2008) Regret in the newsvendor model with partial information. Operations Research, 56(1), 188–203.
   Web of Science ®Google Scholar
• Pollitt, R.J. and Matthews, A.J. (2007) Population quantile-quantile plots for monitoring assay performance in newborn screening. Journal of Inherited Metabolic Disease, 30(4), 607–607.
   Web of Science ®Google Scholar
• Price, S., Golden, B., Wasil, E. and Denton, B.T. (2016) Operations research models and methods in the screening, detection, and treatment of prostate cancer: A categorized, annotated review. Operations Research for Health Care, 8, 9–21.
   Web of Science ®Google Scholar
• Rapisuwon, S., Vietsch, E.E. and Wellstein, A. (2016) Circulating biomarkers to monitor cancer progression and treatment. Computational and Structural Biotechnology Journal, 14, 211–222.
   PubMed Web of Science ®Google Scholar
• Rohlfs, E.M., Zhou, Z., Heim, R.A., Nagan, N., Rosenblum, L.S., Flynn, K., Scholl, T., Akmaev, V.R., Sirko-Osadsa, D.A., Allitto, B.A. and Sugarman, E.A. (2011) Cystic fibrosis carrier testing in an ethnically diverse US population. Clinical Chemistry, 57, 841–848.
   Web of Science ®Google Scholar
• Sato, K.K., Hayashi, T., Harita, N., Yoneda, T., Nakamura, Y., Endo, G. and Kambe, H. (2009). Combined measurement of fasting plasma glucose and hba1c is effective for the prediction of type 2 diabetes: The Kansai healthcare study. Diabetes Care. 32, 644–646.
   PubMed Web of Science ®Google Scholar
• Savage, L.J. (1951) The theory of statistical decision. Journal of the American Statistical Association, 46(253), 55–67.
   Web of Science ®Google Scholar
• Schisterman, E.F., Perkins, N.J., Liu, A. and Bondell, H. (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology, 16(1), 73–81.
   PubMed Web of Science ®Google Scholar
• Sims, E.J., Clark, A., McCormick, J., Mehta, G., Connett, G. and Mehta, A. (2007). Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics, 119(1), 19–28.
   Web of Science ®Google Scholar
• Solvang, H.K., Frigessi, A., Kaveh, F., Riis, M.L., Lüders, T., Bukholm, I.R., Kristensen, V.N. and Andreassen, B.K. (2016) Gene expression analysis supports tumor threshold over 2.0 cm for T-category breast cancer. EURASIP Journal on Bioinformatics and Systems Biology, 2016(1),6–16.
   Google Scholar
• Somoza, E. and Mossman, D. (1992) Comparing and optimizing diagnostic tests: An information-theoretical approach. Medical Decision Making, 12(3), 179–188.
   Web of Science ®Google Scholar
• Sontag, M.K., Hammond, K.B., Zielenski, J., Wagener, J.S. and Accurso, F.J. (2005) Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: Screening efficacy and diagnostic outcomes. The Journal of Pediatrics, 147(3), S83–S88.
   Web of Science ®Google Scholar
• Stephen, J., Murray, G., Cameron, D.A., Thomas, J., Kunkler, I.H., Jack, W., Kerr, G.R., Piper, T., Brookes, C.L., Rea, D. W. and Van De Velde, C.J.H. (2014) Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer, 111(12), 2242–2247.
   Web of Science ®Google Scholar
• Subtil, F. and Rabilloud, M. (2010) A Bayesian method to estimate the optimal threshold of a longitudinal biomarker. Biometrical Journal, 52(3), 333–347.
   Web of Science ®Google Scholar
• Subtil, F. and Rabilloud, M. (2014) Estimating the optimal threshold for a diagnostic biomarker in case of complex biomarker distributions. BMC Medical Informatics and Decision Making, 14(1), 53–63.
   PubMedGoogle Scholar
• Szefler, S.J., Wenzel, S., Brown, R., Erzurum, S.C., Fahy, J.V., Hamilton, R.G., Hunt, J.F., Kita, H., Liu, A.H., Panettieri Jr, R.A. and Schleimer, R.P. (2012) Asthma outcomes: Biomarkers. Journal of Allergy and Clinical Immunology, 129(3), S9–S23.
   Google Scholar
• Therrell, B.L., Hannon, W.H., Hoffman, G., Ojodu, J. and Farrell, P.M. (2012) Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screening. Molecular Genetics and Metabolism, 106(1), 1–6.
   PubMedGoogle Scholar
• Tluczek, A., Mischler, E.H., Farrell, P.M., Fost, N., Peterson, N.M., Carey, P., Bruns, W.T., and McCarthy, C. (1992) Parents’ knowledge of neonatal screening and response to false-positive cystic fibrosis testing. Journal of Developmental and Behavioral Pediatrics: JDBP, 13(3), 181–186.
   PubMed Web of Science ®Google Scholar
• Underwood, D.J., Zhang, J., Denton, B.T., Shah, N.D. and Inman, B.A. (2012) Simulation optimization of PSA-threshold based prostate cancer screening policies. Healthcare Management Science, 15(4), 293–309.
   Web of Science ®Google Scholar
• Van Giessen, A., de Wit, G.A., Moons, K.G., Dorresteijn, J.A. and Koffijberg, H. (2017) An alternative approach identified optimal risk thresholds for treatment indication: An illustration in coronary heart disease. Journal of Clinical Epidemiology, 94, 122–131.
   Web of Science ®Google Scholar
• Vermont, J., Bosson, J., Francois, P., Robert, C., Rueff, A. and Demongeot, J. (1991) Strategies for graphical threshold determination. Computer Methods and Programs in Biomedicine, 35(2), 141–150.
   PubMed Web of Science ®Google Scholar
• Wang, D., McMahan, C.S., Tebbs, J.M. and Bilder, C.R. (2018) Group testing case identification with biomarker information. Computational Statistics & Data Analysis, 122, 156–166.
   PubMed Web of Science ®Google Scholar
• Wein, L.M. and Zenios, S.A. (1996) Pooled testing for HIV screening: Capturing the dilution effect. Operations Research, 44(4), 543–569.
   Web of Science ®Google Scholar
• Wells, J., Rosenberg, M., Hoffman, G., Anstead, M. and Farrell, P.M. (2012) A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. Pediatrics, 129, 339–347.
   Web of Science ®Google Scholar
• Wilson Tang, W.H., Francis, G.S., Morrow, D.A., Newby, L.K., Cannon, C.P., Jesse, R.L., Storrow, A.B., Christenson, R.H., COMMITTEE MEMBERS, Christenson, R.H. and Apple, F.S. (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation, 116(5), e99–e109.
   PubMed Web of Science ®Google Scholar
• Yang, Y., Goldhaber-Fiebert, J.D. and Wein, L.M. (2013) Analyzing screening policies for childhood obesity. Management Science, 59(4), 782–795.
   Web of Science ®Google Scholar
• Ypma, T.J. (1995) Historical development of the Newton–Raphson method. SIAM Review, 37(4), 531–551.
   Web of Science ®Google Scholar
• Yu, W., Liu, T., Valdez, R., Gwinn, M. and Khoury, M.J. (2010) Application of support vector machine modeling for prediction of common diseases: The case of diabetes and pre-diabetes. BMC Medical Informatics and Decision Making, 10(1), 16.
   PubMed Web of Science ®Google Scholar
• Yue, J., Chen, B. and Wang, M. (2006) Expected value of distribution information for the newsvendor problem. Operations Research, 54(6), 1128–1136.
   Web of Science ®Google Scholar
• Zenios, S.A. and Wein, L.M. (1998) Pooled testing for HIV prevalence estimation: exploiting the dilution effect. Statistics in Medicine, 17(13), 1447–1467.
   Web of Science ®Google Scholar
• Zhang, J., Denton, B.T., Balasubramanian, H., Shah, N.D., and Inman, B.A. (2012) Optimization of prostate biopsy referral decisions. Manufacturing & Service Operations Management, 14(4), 529–547.
   Google Scholar